OneMedNet Corp — fact timeline

OneMedNet Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 14, 2026, OneMedNet Corporation (the “Company”) received notice (the “Notice”) from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company, based on the closing bid price of the Company’s common stock for the last 30 consecutive business days, is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a pe”

OneMedNet Corp received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 10, 2025, OneMedNet Corporation (the “Company”) received notice (the “Notice”) from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company, based on the closing bid price of the Company’s common stock for the last 30 consecutive business days, is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a pe”

OneMedNet Corp received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 12, 2025, OneMedNet Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 31 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). The Staff also noted that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed”

OneMedNet Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“March 12, 2025, OneMedNet Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 31 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). The Staff also noted that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed”

Dr. Kenneth Alleyne was appointed as Class III Director at OneMedNet Corp.

“the Board appointed Dr. Kenneth Alleyne to serve as a Class III Director of the Board to fill the vacancy created by the expansion of the Board.”

Robert Golden was appointed as Chief Financial Officer at OneMedNet Corp.

“On January 31, 2025, the Board appointed Mr. Golden as CFO of the Company on a permanent basis.”

OneMedNet Corp reported that prior financial statements should not be relied upon.

“On November 4, 2024, the Audit Committee (the “Audit Committee”) of OneMedNet Corporation (the “Company”) resolved that the Company’s previously issued financial statements (the “Prior Financial Statements”) contained within its Annual Report on Form 10-K for the year ended December 31, 2023, originally filed on April 9, 2024, should no longer be relied upon due to errors in the Prior Financial Statements.”

Sherry Coonse McCraw was elected as Class III Director at OneMedNet Corp.

“elected Sherry Coonse McCraw to the Board as a Class III Director, effective immediately”

Jair Clarke was elected as Class II Director at OneMedNet Corp.

“elected Jair Clarke to the Board as a Class II Director, effective immediately”

Erkan Akyuz resigned as Director at OneMedNet Corp.

“Departure of Directors : Paul Casey and Erkan Akyuz resigned from the Board, effective immediately.”

Paul Casey resigned as Director at OneMedNet Corp.

“Departure of Directors : Paul Casey and Erkan Akyuz resigned from the Board, effective immediately.”

Robert Golden was appointed as Chief Financial Officer at OneMedNet Corp.

“Effective August 30, 2024, the board of directors (the “Board”) of OneMedNet Corporation (the “Company”) appointed Robert Golden to serve as Chief Financial Officer (“CFO”) on an interim basis.”

Lisa Embree resigned as Chief Financial Officer, Executive Vice President, Treasurer and Secretary at OneMedNet Corp.

“Effective August 30, 2024, Lisa Embree departed as the Company’s CFO, Executive Vice President, Treasurer and Secretary.”

Andrew B. Zeinfeld was appointed as Director at OneMedNet Corp.

“Effective August 14, 2024, the Board appointed Mr. Andrew B. Zeinfeld, to serve as a member of the Board to fill the vacancy created by the resignation of Dr. Huh.”

Julianne Huh resigned as Director at OneMedNet Corp.

“On August 12, 2024, Dr. Julianne (Sun Joo) Huh, a member of the Board of Directors (the “Board”) of OneMedNet Corporation (the “Company”) and a member of the Company’s Nominating and Corporate Governance Committee, notified the Company of her resignation from the Company’s Board effective August 12, 2024.”

OneMedNet Corp dismissed BF Borgers CPA PC as its auditor.

“On May 6, 2024, we dismissed BF Borgers CPA PC (“Borgers”) as our independent registered public accounting firm.”

Aaron Green was appointed as Director at OneMedNet Corp.

“Effective March 29, 2024, the Board appointed Mr. Aaron Green, to serve as a member of the Board to fill the vacancy created by the retirement of Scott Holbrook”

Aaron Green was appointed as Chief Executive Officer at OneMedNet Corp.

“Effective March 29, 2024, the Board appointed Mr. Aaron Green, to serve as Chief Executive Officer of the Company to fill the vacancy created by the retirement of Paul Casey.”

Scott Holbrook retired as Director at OneMedNet Corp.

“Also on March 27, 2024, Scott Holbrook, a member of the Board of the Company and a member of the Company’s Audit Committee, notified the Company of his intention to retire from the Company’s Board effective March 29, 2024.”

Paul J. Casey retired as Chief Executive Officer at OneMedNet Corp.

“On March 27, 2024, Paul J. Casey, Chief, Chief Executive Officer of the Company, notified the Company of his intention to retire as Chief Executive Officer of the Company effective March 29, 2024.”

OneMedNet Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“pany’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the Rule, the Company may be eligible for additional time under Listing Rule 5810(c)(3)(A)(ii). The Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency”

OneMedNet Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“February 7, 2024, from the Nasdaq Stock Market (“Nasdaq”) indicating that for the preceding 30 consecutive business days, the market value of the Company’s listed securities (“MVLS”) did not maintain a minimum market value of $50,000,000 (the “Minimum MVLS Requirement”) as required by Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until August 5, 2024, to regain compliance with the Minimum MVLS Requirement. Compliance may be achieved if the Company’s MVLS closes at $50,000,000 or more for a m”

OneMedNet Corp engaged BF Borgers CPA PC as its auditor.

“On December 29, 2023, the Audit Committee (the "Committee") of the Board of Directors of OneMedNet Corporation (f/k/a Data Knights Acquisition Corp.) (the "Company") dismissed Marcum LLP ("Marcum"), the Company's independent registered public accounting firm since its inception on February 8, 2021 and approved the appointment of BF Borgers CPA PC ("Borgers") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2023.”

OneMedNet Corp dismissed Marcum LLP as its auditor.

“On December 29, 2023, the Audit Committee (the "Committee") of the Board of Directors of OneMedNet Corporation (f/k/a Data Knights Acquisition Corp.) (the "Company") dismissed Marcum LLP ("Marcum"), the Company's independent registered public accounting firm since its inception on February 8, 2021 and approved the appointment of BF Borgers CPA PC ("Borgers") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2023.”

OneMedNet Corp reported that prior financial statements should not be relied upon.

“On November 20, 2023, OneMedNet Corporation (f/k/a Data Knights Acquisition Corp.) (the “Company”) determined that the Company’s unaudited consolidated financial statements and the notes thereto as of September 30, 2023 included in the Company’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 20, 2023 (the “Form 10-Q”) should no longer be relied upon.”

OneMedNet Corp: Data Knights ceased being a shell company as a result of the Business Combination.

“As a result of the Business Combination, Data Knights ceased being a shell company”

OneMedNet Corp: Adopted a new Code of Business Conduct and Ethics (effective 2023-11-09).

“On November 9, 2023, the Company adopted a new Code of Business Conduct and Ethics that applies to all of its employees, officers and directors, including its Chief Executive Officer, Chief Financial Officer and other executive and senior financial officers”

OneMedNet Corp: Adopted Amended and Restated Bylaws effective as of the Closing Date.

“OneMedNet adopted the Third Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws effective as of the Closing Date”

OneMedNet Corp: Adopted Third Amended and Restated Certificate of Incorporation effective as of the Closing Date.

“OneMedNet adopted the Third Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws effective as of the Closing Date”

OneMedNet Corp underwent a change of control involving Data Knights Acquisition Corp. (closed 2023-11-07).

“On November 7, 2023, following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17, 2023 (the “ Special Meeting ”), Data Knights Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”) and a wholly-owned subsidiary of Data Knights Acquisition Corp., a Delaware corporation (“ Data Knights ”), consummated a merger (the “ Merger ”) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (“ OneMedNet ”) pursuant to an agreement and plan of merger, dated as of April 25, 2022 (the “ Merger Agreement ”), by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (“ Sponsor ” or “ Purchaser Representative ”) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the stockholders of OneMedNet (“ Seller Representative ”).”

OneMedNet Corp shareholders approved Approval to adjourn the Special Meeting if necessary to permit further solicitation and vote (Adjournment Proposal) at the 2023-10-17 meeting.

“Proposal 7 : To approve adjourning the Special Meeting to a later date or dates, if necessary to permit further solicitation and vote of proxies if it is determined by the Company that more time is necessary or appropriate to approve one or more Proposals at the Special Meeting (the “Adjournment Proposal”). The voting results for the Adjournment Proposal were as follows: For Against Abstain 4,680,323 10,242 0”

OneMedNet Corp shareholders approved Approval of 2022 Equity Incentive Plan at the 2023-10-17 meeting.

“Proposal 6 : To approve the 2022 Equity Incentive Plan (the “Incentive Plan Proposal”). The voting results for the Incentive Plan Proposal were as follows: For Against Abstain 4,520,354 170,211 0”

OneMedNet Corp shareholders approved Election of eight directors to serve following consummation of Business Combination at the 2023-10-17 meeting.

“Proposal 5 : To elect eight directors to serve on the Company’s board of directors following the consummation of the Business Combination until the 2024 annual meeting of Stockholders, in the case of Class I directors, the 2025 annual meeting of Stockholders, in the case of Class II directors, and the 2026 annual meeting of Stockholders, in the case of Class III directors, and, in each case, until their respective successors are duly elected and qualified (the “Director Election Proposal”). The voting results for the Director Election Proposal were as follows: Director For Withheld Erkan Akyuz (Class I) 4,685,885 4,680 Eric Casaburi (Class I) 4,685,885 4,680 Dr. Julianne Huh (Class II) 4,685,885 4,680 Paul Casey (Class II) 4,685,885 4,680 Dr. Thomas Kosasa (Class II) 4,685,885 4,680 Dr. Jeffrey Yu (Class III) 4,525,916 164,649 Robert Golden (Class I) 4,685,885 4,680 R. Scott Holbrook (Class III) 4,685,885 4,680”

OneMedNet Corp shareholders approved Approval of supermajority voting requirement to amend certain Articles of the Certificate of Incorporation (Article Amendment Requirement) at the 2023-10-17 meeting.

“Proposal 4B : To approve the addition to the Company’s Certificate of Incorporation of a super majority voting requirement (the “Article Amendment Requirement”) to amend Articles V (Board of Directors), VI (Stockholders), VII (Liability and Indemnification; Corporate Opportunity), VIII (Business Combinations), IX (Exclusive Forum), and Article X (Amendments) of the Third Amended and Restated Certificate of Incorporation. The voting results for the Article Amendment Requirement were as follows: For Against Abstain 4,520,354 170,211 0”

OneMedNet Corp shareholders approved Approval of supermajority voting requirement to amend Bylaws (Bylaw Amendment Requirement) at the 2023-10-17 meeting.

“Proposal 4A : To approve the addition to Company’s Certificate of Incorporation of a super majority voting requirement to amend the Surviving Corporation’s Bylaws (the “Bylaw Amendment Requirement”), as contained in the Third Amended and Restated Certificate of Incorporation. The voting results for the Bylaw Amendment Requirement were as follows: For Against Abstain 4,520,354 170,211 0”

OneMedNet Corp shareholders approved Approval of Third Amended and Restated Certificate of Incorporation upon closing of Business Combination (Charter Amendment Proposal) at the 2023-10-17 meeting.

“Proposal 4 : To approve the Third Amended and Restated Certificate of Incorporation, which shall become effective upon the closing of the Business Combination (the “Charter Amendment Proposal”), including (i) the addition of a supermajority voting requirement to amend the Surviving Corporation’s Bylaws, and (ii) the addition of a supermajority voting requirement to amend Articles V (Board of Directors), VI (Stockholders), VII (Liability and Indemnification; Corporate Opportunity), VIII (Business Combinations), IX (Exclusive Forum), and Article X (Amendments) to the Third Amended and Restated Certificate of Incorporation. The voting results for the Charter Amendment Proposal were as follows: For Against Abstain 4,520,354 170,211 0”

OneMedNet Corp shareholders approved Approval of issuance of more than 20% of issued and outstanding Class A common stock and resulting change in control in connection with the Business Combination (Nasdaq Proposal) at the 2023-10-17 meeting.

“Proposal 3 : To approve, for purposes of complying with Nasdaq Listing Rules 5635(a) and (b), the issuance of more than 20% of the issued and outstanding Class A common stock and the resulting change in control in connection with the Business Combination (the “Nasdaq Proposal”). The voting results for the Nasdaq Proposal were as follows: For Against Abstain 4,680,323 10,242 0”

OneMedNet Corp shareholders approved Approval and adoption of the Merger Agreement and the transactions contemplated thereby (Business Combination Proposal) at the 2023-10-17 meeting.

“Proposal 2 : To approve and adopt the Merger Agreement and approve the transactions contemplated thereby (the “Business Combination Proposal”). The voting results for the Business Combination Proposal were as follows: For Against Abstain 4,680,323 10,242 0”

OneMedNet Corp shareholders approved Approval of amendment to the Charter to remove the redemption limitation at the 2023-10-17 meeting.

“Proposal 1 : To approve an amendment to the Second Amendment to the Second Amended and Restated Certificate of Incorporation (the “Charter”) effective prior to the consummation of the Business Combination, to remove from the Charter the redemption limitation contained under Section 9.2(a) preventing the Company from closing a business combination if it would have less than $5,000,0001 of net tangible assets (the “NTA Proposal”). The voting results for the NTA Proposal were as follows: For Against Abstain 4,590,735 5,562 0”

OneMedNet Corp: Amended charter to extend deadline for business combination up to nine one-month extensions through May 11, 2024, with deposit of extension amount into trust account.

“promptly filed the Amended Charter with the Secretary of State of the State of Delaware.”

OneMedNet Corp shareholders approved Trust Amendment Proposal to amend the Trust Agreement to change the termination date of the trust.

“The stockholders approved the Extension Amendment Proposal.”

OneMedNet Corp shareholders approved Extension Amendment Proposal to amend the Company's Amended and Restated Certificate of Incorporation to extend the date by which the Company must consummate a business combination.

“The Stockholders approved the Extension Amendment Proposal.”

OneMedNet Corp: Approved First Amendment to the Second Amended and Restated Certificate of Incorporation to extend the deadline to complete a business combination from November 11, 2022, up to August 11, 2023, through up to nine one-month extensions (effective 2022-11-11).

“The stockholders of the Company approved the First Amendment to the Second Amended and Restated Certificate of Incorporation of the Company at the November 11, 2022, special meeting, giving the Company the right to extend the date by which the Company must (i) consummate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination involving the Company and one or more businesses (a “business combination”), (ii) cease its operations if it fails to complete such business combination, and (iii) redeem or repurchase 100% of the Company’s Class A common stock included as part of the units sold in the Company’s initial public offering that was closed on May 11, 2021 (the “IPO”) from November 11, 2022 (the “Termination Date”) up to nine (9) one-month extensions to August 11, 2023 (the “Extension Amendment Proposal”).”

OneMedNet Corp shareholders approved Trust Amendment Proposal to amend the Investment Management Trust Agreement to extend the date on which the trustee must liquidate the Trust Account from November 11, 2022 to August 11, 2023 at the 2022-11-11 meeting.

“Proposal 2 - Trust Amendment Proposal The Stockholders approved the Trust Amendment Proposal, pursuant to which the Investment Management Trust Agreement (the “Trust Agreement”), dated May 11, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as trustee (“Continental”), was amended to extend the date on which Continental must liquidate the Trust Account (the “Trust Account”) established in connection with the IPO if the Company has not completed its initial business combination, from November 11, 2022 to August 11, 2023 (or such earlier date after November 11, 2022, as determined by the Data Knights Board). The following is a tabulation of the voting results: Common Stock: Votes For Votes Against Abstentions Broker Non-Votes 10,778,719 927,199 – –”

OneMedNet Corp shareholders approved Extension Amendment Proposal to extend the date by which the Company must consummate a business combination from November 11, 2022 to August 11, 2023 at the 2022-11-11 meeting.

“Proposal 1- Extension Amendment Proposal The Stockholders approved the Extension Amendment Proposal, giving the Company the right to extend the date by which the Company must (i) consummate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination involving the Company and one or more businesses (a “business combination”), (ii) cease its operations if it fails to complete such business combination, and (iii) redeem or repurchase 100% of the Company’s Class A common stock included as part of the units sold in the Company’s initial public offering that was closed on May 11, 2021 (the “IPO”) from November 11, 2022 (the “Termination Date”) up to nine (9) one-month extensions to August 11, 2023. The following is a tabulation of the voting results: Common Stock: Votes For Votes Against Abstentions Broker Non-Votes 10,778,720 927,198 – –”